{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T23:00:14Z","timestamp":1781305214088,"version":"3.54.1"},"reference-count":40,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2007,11,1]],"date-time":"2007-11-01T00:00:00Z","timestamp":1193875200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Autoimmunity Reviews"],"published-print":{"date-parts":[[2007,11]]},"DOI":"10.1016\/j.autrev.2007.03.003","type":"journal-article","created":{"date-parts":[[2007,3,27]],"date-time":"2007-03-27T11:17:49Z","timestamp":1174994269000},"page":"35-41","source":"Crossref","is-referenced-by-count":103,"title":["Biological and clinical effects of anti-TNF\u03b1 treatment"],"prefix":"10.1016","volume":"7","author":[{"given":"G.","family":"Valesini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Iannuccelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Marocchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Pascoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Scalzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Di Franco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.autrev.2007.03.003_bib1","first-page":"241","article-title":"Molecular differences in anticytokine therapies","volume":"21","author":"Calabrese","year":"2003","journal-title":"Clin Exp Rheumatol"},{"issue":"2","key":"10.1016\/j.autrev.2007.03.003_bib2","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1124\/jpet.301.2.418","article-title":"Binding and functional comparisons of two types of tumor necrosis factor antagonists","volume":"301","author":"Scallon","year":"2002","journal-title":"J Pharmacol Exp Ther"},{"issue":"6","key":"10.1016\/j.autrev.2007.03.003_bib3","doi-asserted-by":"crossref","first-page":"478","DOI":"10.7326\/0003-4819-130-6-199903160-00004","article-title":"Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial","volume":"130","author":"Moreland","year":"1999","journal-title":"Ann Intern Med"},{"issue":"9410","key":"10.1016\/j.autrev.2007.03.003_bib4","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/S0140-6736(04)15640-7","article-title":"TEMPO study investigators. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial","volume":"363","author":"Klareskog","year":"2005","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.autrev.2007.03.003_bib5","first-page":"1232","article-title":"Long-term safety, efficacy, and radiographic outcome with etanercept treatment in patients with early rheumatoid arthritis","volume":"32","author":"Genovese","year":"2005","journal-title":"J Rheumatol"},{"issue":"22","key":"10.1016\/j.autrev.2007.03.003_bib6","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1056\/NEJM200011303432202","article-title":"Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group","volume":"343","author":"Lipsky","year":"2000","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.autrev.2007.03.003_bib7","doi-asserted-by":"crossref","first-page":"3432","DOI":"10.1002\/art.20568","article-title":"Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial","volume":"50","author":"St Clair","year":"2004","journal-title":"Arthritis Rheum"},{"issue":"11","key":"10.1016\/j.autrev.2007.03.003_bib8","doi-asserted-by":"crossref","first-page":"3381","DOI":"10.1002\/art.21405","article-title":"Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial","volume":"52","author":"Goekoop-Ruiterman","year":"2005","journal-title":"Arthritis Rheum"},{"issue":"5","key":"10.1016\/j.autrev.2007.03.003_bib9","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1136\/ard.2003.013052","article-title":"Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed","volume":"63","author":"van de Putte","year":"2004","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.autrev.2007.03.003_bib10","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1002\/art.10697","article-title":"Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial","volume":"48","author":"Weinblatt","year":"2003","journal-title":"Arthritis Rheum"},{"issue":"12","key":"10.1016\/j.autrev.2007.03.003_bib11","first-page":"2563","article-title":"Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis)","volume":"30","author":"Furst","year":"2003","journal-title":"J Rheumatol"},{"issue":"5","key":"10.1016\/j.autrev.2007.03.003_bib12","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1002\/art.20217","volume":"50","author":"Keystone","year":"2004","journal-title":"Arthritis Rheum"},{"issue":"Suppl III","key":"10.1016\/j.autrev.2007.03.003_bib13","first-page":"423","article-title":"Adalimumab (Humira\u00ae) is effective in patients who have previously been treated with TNF-antagonists (etanercept and\/or infliximab) in widespread clinical practice: 12-week outcomes in the ReAct trial","volume":"64","author":"Burmester","year":"2005","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.autrev.2007.03.003_bib14","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1002\/art.21519","volume":"54","author":"Breedveld","year":"2002","journal-title":"Arthritis Rheum"},{"issue":"5","key":"10.1016\/j.autrev.2007.03.003_bib15","first-page":"959","article-title":"Infliximab in ankylosing spondylitis: a prospective observational inception cohort analysis of efficacy and safety","volume":"29","author":"Maksymowych","year":"2002","journal-title":"J Rheumatol"},{"issue":"2","key":"10.1016\/j.autrev.2007.03.003_bib16","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1002\/art.20852","article-title":"Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT)","volume":"52","author":"van der Heijde","year":"2005","journal-title":"Arthritis Rheum"},{"issue":"18","key":"10.1016\/j.autrev.2007.03.003_bib17","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1056\/NEJMoa012664","article-title":"Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha","volume":"346","author":"Gorman","year":"2002","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.autrev.2007.03.003_bib18","doi-asserted-by":"crossref","first-page":"2506","DOI":"10.1002\/art.21209","article-title":"The comparative effectiveness of tumor necrosis factor-blocking agents in patients with rheumatoid arthritis and patients with ankylosing spondylitis: a six-month, longitudinal, observational, multicenter study","volume":"52","author":"Heiberg","year":"2005","journal-title":"Arthritis Rheum"},{"issue":"Suppl III","key":"10.1016\/j.autrev.2007.03.003_bib19","first-page":"313","article-title":"Adalimumab efficacy in patients with psoriatic arthritis who failed prior DMARD therapy","volume":"64","author":"Genovese","year":"2005","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"10.1016\/j.autrev.2007.03.003_bib20","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1097\/01.bor.0000231901.19795.8a","article-title":"Update on anti-tumor necrosis factor therapy in the spondyloarthropathies including psoriatic arthritis","volume":"18","author":"Kavanaugh","year":"2006","journal-title":"Curr Opin Rheumatol"},{"issue":"4","key":"10.1016\/j.autrev.2007.03.003_bib21","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.cyto.2005.12.012","article-title":"Anti-TNF therapies in the management of acute and chronic uveitis","volume":"33","author":"Hale","year":"2006","journal-title":"Cytokine"},{"issue":"12","key":"10.1016\/j.autrev.2007.03.003_bib22","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1136\/ard.2006.052092","article-title":"Efficacy of tumor necrosis factor blockers in reducing uveitis flares in patients with spondylarthropathy: a retrospective study","volume":"65","author":"Guignard","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2007.03.003_bib23","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1191\/0961203305lu2240rr","article-title":"The effect of TNFalpha blockade on the antinuclear antibody profile in patients with chronic arthritis: biological and clinical implications","volume":"14","author":"De Rycke","year":"2005","journal-title":"Lupus"},{"key":"10.1016\/j.autrev.2007.03.003_bib24","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1002\/art.11098","article-title":"Tumor necrosis factor alpha blockade reduces the synovial cell infiltrate early after initiation of treatment, but apparently not by induction of apoptosis in synovial tissue","volume":"48","author":"Smeets","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2007.03.003_bib25","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1136\/ard.2003.018085","article-title":"Early effects of tumour necrosis factor alpha blockade on skin and synovial tissue in patients with active psoriasis and psoriatic arthritis","volume":"63","author":"Goedkoop","year":"2004","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2007.03.003_bib26","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1002\/art.20764","article-title":"Evidence that anti-tumor necrosis factor therapy with both etanercept and infliximab induces apoptosis in macrophages, but not lymphocytes, in rheumatoid arthritis joints: extended report","volume":"52","author":"Catrina","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2007.03.003_bib27","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1084\/jem.192.9.1353","article-title":"C-reactive protein binds to apoptotic cells, protect the cells from assembly of the terminal complement components, and sustains an antiinflammatory innate immune response: implications for systemic autoimmunity","volume":"192","author":"Gershow","year":"2000","journal-title":"J Exp Med"},{"key":"10.1016\/j.autrev.2007.03.003_bib28","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1084\/jem.20012094","article-title":"Delayed apoptotic cell clearance and lupus-like autoimmunity in mice lacking the c-mer membrane tyrosine kinase","volume":"196","author":"Cohen","year":"2002","journal-title":"J Exp Med"},{"key":"10.1016\/j.autrev.2007.03.003_bib29","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/s00296-004-0542-1","article-title":"Anti-TNF\u03b1 therapy in rheumatoid arthritis and autoimmunity","volume":"26","author":"Caramaschi","year":"2006","journal-title":"Rheumatol Int"},{"issue":"9306","key":"10.1016\/j.autrev.2007.03.003_bib30","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/S0140-6736(02)07714-0","article-title":"Drug-induced systemic lupus erythematosus associated with etanercept therapy","volume":"359","author":"Shakoor","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.autrev.2007.03.003_bib31","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1002\/art.10876","article-title":"antinuclear antibodies following infliximab treatment in patients with rheumatoid arthritis or spondyloarthritis","volume":"48","author":"De Rycke","year":"2003","journal-title":"Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.autrev.2007.03.003_bib32","doi-asserted-by":"crossref","first-page":"R3","DOI":"10.1186\/ar1851","article-title":"Adalimumab clinical efficacy is associated with rheumatoid factor and anti-cyclic citrullinated peptide antibody titer reduction: a one-year prospective study","volume":"8","author":"Atzeni","year":"2006","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.autrev.2007.03.003_bib33","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1136\/ard.2004.024182","article-title":"Autoantibody formation in patients with rheumatoid arthritis treated with anti-TNF alpha","volume":"64","author":"Eriksson","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2007.03.003_bib34","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1002\/art.21671","article-title":"Development of antiinfliximab antibodies and relationship to clinical response in patients with rheumatoid arthritis","volume":"54","author":"Wolbink","year":"2006","journal-title":"Arthritis Rheum"},{"issue":"10","key":"10.1016\/j.autrev.2007.03.003_bib35","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1136\/ard.2003.014647","article-title":"Decrease of anti-cyclic citrullinated peptide antibodies and rheumatoid factor following anti-TNFalpha therapy (infliximab) in rheumatoid arthritis is associated with clinical improvement","volume":"63","author":"Alessandri","year":"2004","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.autrev.2007.03.003_bib36","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1136\/ard.2005.038851","article-title":"The effect of etanercept on anti-cyclic citrullinated peptide antibodies and rheumatoid factor in patients with rheumatoid arthritis","volume":"65","author":"Chen","year":"2006","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"10.1016\/j.autrev.2007.03.003_bib37","first-page":"497","article-title":"Anti-cyclic citrullinated protein antibodies as a predictor of response to anti-tumor necrosis factor-alpha therapy in patients with rheumatoid arthritis","volume":"33","author":"Braun-Moscovici","year":"2006","journal-title":"J Rheumatol"},{"issue":"Suppl 1(4)","key":"10.1016\/j.autrev.2007.03.003_bib38","first-page":"1","article-title":"Are there differences among anti-TNFalpha biological drugs?","volume":"57","author":"Valesini","year":"2005","journal-title":"Reumatismo"},{"issue":"4","key":"10.1016\/j.autrev.2007.03.003_bib39","first-page":"413","article-title":"Recommendations for the use of biologic (TNF-alpha blocking) agents in the treatment of rheumatoid arthritis in Italy","volume":"24","author":"Valesini","year":"2006","journal-title":"Clin Exp Rheumatol"},{"issue":"7","key":"10.1016\/j.autrev.2007.03.003_bib40","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1056\/NEJMct055183","article-title":"Tumor necrosis factor inhibitors for rheumatoid arthritis","volume":"355","author":"Scott","year":"2006","journal-title":"N Engl J Med"}],"container-title":["Autoimmunity Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997207000778?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997207000778?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,8,11]],"date-time":"2021-08-11T20:54:50Z","timestamp":1628715290000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1568997207000778"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,11]]},"references-count":40,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2007,11]]}},"alternative-id":["S1568997207000778"],"URL":"https:\/\/doi.org\/10.1016\/j.autrev.2007.03.003","relation":{},"ISSN":["1568-9972"],"issn-type":[{"value":"1568-9972","type":"print"}],"subject":[],"published":{"date-parts":[[2007,11]]}}}